104
Participants
Start Date
January 19, 2022
Primary Completion Date
September 22, 2022
Study Completion Date
December 19, 2022
Oxervate
Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
Vehicle
Vehicle will be instilled with the same scheme of the test product
Università degli Studi di Milano - Ospedale San Giuseppe - UO Oculistica, Milan
The Johns Hopkins University, Baltimore
Virginia Eye Consultants (VEC) - Norfolk Office, Norfolk
Toyos Clinic - Nashville, Nashville
Houston Eye Associates HEA - Gramercy Location, Houston
Lugene Eye Institute - Glendale Office, Glendale
David Wirta, M.D. & Associates, Newport Beach
AOU Gaspare Rodolico - Ospedale San Marco, Catania
Tufts University School of Medicine (TUSM) - New England Eye Center/Tufts Medical Center - Boston, Boston
AOU Policlinico Umberto I - Dipartimento Organi di Senso - Clinica Oculistica, Roma
Dompé Farmaceutici S.p.A
INDUSTRY